knowledge -WSS

knowledge

author：explore 2025-09-06 02:11:25 - browse：2

Alex Hogan/STAT

The J.P. Morgan Healthcare Conference is upon us, bringing its frenetic meetings, crowded hallways, and hotel rooms so expensive that even the pharmaceutical industry complains about what a free market does to the prices of scarce goods.

This year’s iteration, starting Monday in San Francisco, finds the biotech industry, in particular, in a curious spot. After a volatile 2023 that saw biotech stocks hit five-year lows in the fall, the sector had a bull run in the final weeks of the year, spurred by some high-dollar merger agreements and a prevailing sense that the macroeconomic winds were finally shifting in biotech’s direction.

Meanwhile, companies selling digital health services like telemedicine, health plans for virtual care, and AI tools for payers face a crucial year as they scramble to make good on profitability projections. Those companies, along with the country’s most powerful health systems, are seriously exploring AI, even ChatGPT, to help them meet financial milestones.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： TikTok, Instagram influencers need more rules for drug ads

knowledge

WSS

Future doctors need a strong humanities education

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

To avoid data mishandling cases, universities eye AI and other tools

Private equity deals in Medicare Advantage declines

Readout LOUD podcast: How biotech is using artificial intelligence

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

hotspot

knowledge

focus

Novavax promises a turnaround & Lilly roils the obesity market

To avoid data mishandling cases, universities eye AI and other tools

Psychedelics group wrestles with new pharma identity

Inaction leaves children at risk from dangerous chemotherapy drug

Bright Health sells Medicare Advantage business to Molina

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

New air purifier tech could be key to improving indoor air quality

Medical mystery: When a cough is not just a cough

The cancer drug shortage isn’t new — and neither are the solutions

Immunocompromised patients offer clues on chronic Covid

entertainment

Doctors' information doesn't help them choose wisely when sick

Readout LOUD podcast: How biotech is using artificial intelligence

To avoid data mishandling cases, universities eye AI and other tools

PhRMA lawsuit over Medicare drug price negotiation tossed

Prior authorization reform is both possible and imperative

Head of FDA's diagnostics center, who led through Covid, retires

knowledge

leisure time

leisure time

Wikipedia